

5th International Electronic Conference on Medicinal Chemistry

1-30 November 2019 chaired by Dr. Jean Jacques Vanden Eynde

sponsored by
pharmaceuticals

Disclosing the effect of doxorubicin and mitoxantrone on cardiac mitochondrial proteome: an *in vivo* approach using a murine model

Sofia Brandão^{1,2,*}, Ana Reis-Mendes¹, Félix Carvalho¹, Maria Bastos¹, Rita Ferreira², Vera Costa¹

 ¹ UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, R. Jorge de Viterbo Ferreira 228, 4050-313 Porto, Portugal;
 ² Mass Spectrometry Group, QOPNA & LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.

* Corresponding author: sofiarbrandao@ua.pt



Disclosing the effect of doxorubicin and mitoxantrone on cardiac mitochondrial proteome: an *in vivo* approach using a murine model







Abstract

The number of cancer survivors has increased considerably due to the current therapies. Nevertheless, the cardiac side effects in these patients are still a concern. Our goal was to study the effects of doxorubicin (DOX) and mitoxantrone (MTX) on the molecular mechanisms harbored in the heart of male mice. Six intraperitoneal administrations were given to the animals. DOX- and MTX-treated animals received a total cumulative dose of 9 and 6 mg/kg, respectively. Whole cardiac tissue and corresponding enriched mitochondrial fractions were analyzed by immunoblot and enzymatic techniques. Additionally, enriched mitochondrial fractions were studied by mass spectrometry-based proteomics. From this analysis 693 different proteins were identified, assigned to the biological processes "small molecule metabolic process", "oxidation-reduction process" and "carboxylic acid metabolic process". The distribution analysis of the mitochondrial proteome data showed clustering among the conditions. Indeed, MTX treatment presented less similarities with control. Moreover, DOX and MTX promoted a decrease on mitochondrial density. Metabolic adaptations were noticed, more evident for DOX. Concomitantly, metabolic adaptations were noticed, more evident in the heart of DOX treated mice. Indeed, increased GAPDH-to-ATP and ETFDH-to-ATP ratios were observed. Thus, more than differences in cardiac mitochondrial proteome, these drugs seem to decrease this organelle density.

Keywords: anticancer drugs; cardiotoxicity; proteomics; mitochondria





In the last decades, the number of cancer survivors has increased considerably due to the huge efficacy of <u>anticancer therapies</u>, namely earlier detection and improved treatment.



Roser M, et al. Cancer. 2019; OurWorldInData.org



5th International Electronic Conference on Medicinal Chemistry 1-30 November 2019

sponsors: MDPI pharmaceuticals

Among the several anticancer therapies, chemotherapy is the most frequently used.



Roser M, et al. Cancer. 2019; OurWorldInData.org Colombo A, et al. Curr Treat Options Cardiovasc Med. 2014;16(6):313





However, the <u>chemotherapeutic agents</u> affect non-cancer cells leading to adverse side effects, such as fatigue, alopecia, <u>cardiotoxicity</u> and neurotoxicity.



Hrynchak I, et al. Drug Metab Rev. 2017;49(2):158–96 Colombo A, et al. Curr Treat Options Cardiovasc Med. 2014;16(6):313





Both DOX and MTX seem to affect **cardiac mitochondrial dynamics**, although the exact mechanism of action is still unclear.



Our goal was to study the effects of DOX and MTX on the cardiac

mitochondrial proteome remodeling of adult male CD-1 mice.

McGowan JV, et al. Cardiovasc Drugs Ther. 2017;31(1):63-75





Methods



• 6 mg/kg for MTX animals

pharmaceuticals

sponsors:

Animal welfare was assessed daily during the entire experimental period.

The experiments were performed with the approval of the Portuguese National Authority for Animal Health (reference number 0421/000/000/2016) and of the ORBEA of ICBAS-UP (project number 140/2015).



Methods



Statistical analysis was performed with GraphPad Prism (version 6.0.1).

Experimental groups were compared using ordinary one-way ANOVA followed by Turkey's multiple comparisons test (*p* < 0.05).

GeLC-MS/MS: combines one dimensional SDS-PAGE with liquid chromatography-tandem mass spectrometry







Effect of DOX and MTX on morphometric parameters

 Whole body weight (g) Heart mass (g) Heart mass-to-whole body weight (mg/g) Heart mitochondrial isolation yield (mtDNA-to-tDNA) Results are presented as significantly increased (1), decreased 	† † †	+
Heart mass (g) Heart mass-to-whole body weight (mg/g) Heart mitochondrial isolation yield (mtDNA-to-tDNA) Results are presented as significantly increased (1), decreased	\Leftrightarrow	
Heart mass-to-whole body weight (mg/g) Heart mitochondrial isolation yield (mtDNA-to-tDNA) Results are presented as significantly increased (1), decrea	$ \Longleftrightarrow $	4
Heart mitochondrial isolation yield (mtDNA-to-tDNA) Results are presented as significantly increased (1), decreased		
Results are presented as significantly increased (1), decreased	$ \Longleftrightarrow $	$ \Longleftrightarrow $
significantly different () related to the control group.	ased () or no
OX and MTX administration did not induce signif	icant d	differen

on morphometric parameters compared to control mice.

mtDNA: mitochondrial deoxyribonucleic acid; tDNA: total deoxyribonucleic acid







Results and discussion



Effect of DOX and MTX on mitochondrial biogenesis

	DOX	ΜΤΧ
CS activity (nmol·mg ^{-1.} min ⁻¹)		Ļ
PGC-1alpha (arbitrary units of optical density)		
PGC-1alpha/CS activity	$ \Longleftrightarrow $	$ \Longleftrightarrow $
Results are presented as significantly increased (1), on significantly different (decrease	d (I) or

CS: citrate synthase; PGC-1alpha: peroxisome proliferator-activated receptor y coactivator 1 alpha





Results and discussion



Effect of DOX and MTX on metabolism

	DOX	MTX
ATP-B (arbitrary units of optical density)	$ \Longleftrightarrow $	$ \Longleftrightarrow $
GAPDH (arbitrary units of optical density)	$ \Longleftrightarrow $	$ \Longleftrightarrow $
GAPDH/ATP-B	1	\leftrightarrow
ETFDH (arbitrary units of optical density)		$ \Longleftrightarrow $
ETFDH/ATP-B	1	$ \Longleftrightarrow $
Results are presented as significantly increased (or no significantly different (+) related to the con	1), decre	ased (‡) Jp.

ATP-B: ATP synthase beta; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; ETFDH: electron transfer flavoprotein dehydrogenase







Effect of DOX and MTX on mitochondrial biogenesis and metabolism

DOX and MTX administration promoted decreased mitochondrial density compared to control mice;

DOX administration led to increased GAPDH/ATP-B and ETFDH/ATP-B

ratios compared to control mice.





MTX



Effect of DOX and MTX on cardiac mitochondria proteome remodeling

		DOX	MTX
	CS activity (nmol·mg ^{-1.} min ⁻¹)	$ \Longleftrightarrow $	$ \Longleftrightarrow $
	ATP synthase activity (µmol·mg ⁻¹ ·min ⁻¹)	$ \Longleftrightarrow $	$ \Longleftrightarrow $
	ATP-B (arbitrary units of optical density)	$ \Longleftrightarrow $	\Leftrightarrow
	MnSOD (arbitrary units of optical density)	$ \Longleftrightarrow $	Ļ
	Results are presented as significantly increased (1 or no significantly different (+) related to the con), decre trol grou	ased (‡) ıp.
ac	Iministration induce decrease on the	antio	xidant

MnSOD compared to control mice.

CS: citrate synthase; ATP-B: ATP synthase beta; MnSOD: manganese superoxide dismutase







Distribution analysis

* Szklarczyk D, et al. Nucleic Acids Res. 2015;43(D1):D447–52





Results and discussion



Effect of DOX and MTX on cardiac mitochondria proteome remodeling



Distribution analysis*

Clustering among the groups;

MTX administration presented less similarities with control mice than DOX administration.

* Based on partial least squares-discriminant analysis (PLS-DA) of free available MetaboAnalyst 4.0 software (http://www.metaboanalyst.ca)





 \checkmark



- Decreased mitochondrial density in cardiac muscle;
- Metabolic adaptations more evident in the heart of DOX animals.
- MTX seems to have a higher impact on the remodeling of mitochondrial proteome.





This work was supported by national funds by Fundação para a Ciência e a Tecnologia (FCT, Portugal) and co-financed by FEDER and COMPETE for the project "PTDC/DTP-FTO/1489/2014 – POCI-01-0145-FEDER-016537" and the QOPNA research unit (FCT UID/QUI/00062/2019).

SRB, ARM and VMC acknowledge FCT for their grants (SFRH/BD/138202/2018, SFRH/BD/129359/2017 and SFRH/BPD/110001/2015) and VMC's grant is funded by FCT, I.P., under the Norma Transitória – DL57/2016/CP1334/CT0006.









5th International Electronic Conference on Medicinal Chemistry 1-30 November 2019





pharmaceuticals